June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Suprachoroidal Microinjection of Triamcinolone Acetonide is Well Tolerated in the Albino Rabbit
Author Affiliations & Notes
  • Rozemarijn Verhoeven
    Clearside Biomedical, Alpharetta, GA
  • Samirkumar Patel
    Clearside Biomedical, Alpharetta, GA
  • Karen Viaud-Quentric
    Iris Pharma, La Gaude, France
  • Florian Cacciamani
    Iris Pharma, La Gaude, France
  • Thierry Amar
    Iris Pharma, La Gaude, France
  • Benjamin Yerxa
    Clearside Biomedical, Alpharetta, GA
  • Footnotes
    Commercial Relationships Rozemarijn Verhoeven, Clearside Biomedical (E); Samirkumar Patel, Clearside Biomedical (E), Clearside Biomedical (I), Clearside Biomedical (P); Karen Viaud-Quentric, Iris Pharma (E); Florian Cacciamani, Iris pharma (E); Thierry Amar, None; Benjamin Yerxa, Clearside Biomedical (I)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 119. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rozemarijn Verhoeven, Samirkumar Patel, Karen Viaud-Quentric, Florian Cacciamani, Thierry Amar, Benjamin Yerxa; Suprachoroidal Microinjection of Triamcinolone Acetonide is Well Tolerated in the Albino Rabbit. Invest. Ophthalmol. Vis. Sci. 2013;54(15):119.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To evaluate ocular tolerability and toxicokinetics of suprachoroidal administration of triamcinolone acetonide (TA) using a Clearside Biomedical proprietary microneedle in a GLP study in the New Zealand White rabbit.

Methods: On Day 0, rabbits (5/sex/group) were administered a single bilateral suprachoroidal injection of vehicle, 3.2 mg or 5.2 mg of TA (Triesence®) using a 33g 750µm microneedle. Clinical observations, body weights, food and water consumption, slit lamp biomicroscopy with McDonald-Shadduck scoring, fundus evaluation, intraocular pressure assessment (IOP), electroretinography (ERG), and systemic exposure were assessed up to 17 weeks post-dose. Animals were sacrificed on Day 1 and Week 13 for macroscopic observations, ocular toxicokinetics, and ocular histopathology.

Results: There were no adverse effects related to test article or method of administration on clinical observations, body weight, body weight gain, food and water consumption, or ophthalmic examinations. No effect on ERG a- or b-wave amplitude or implicit time was noted in any animal. A mild, transient increase in IOP of 2-3 mmHg was observed in the TA groups on Days 7 and 28, which resolved by Week 13 and was not considered adverse. Inflammatory cells and test article were observed in the suprachoroidal space of TA-treated animals on Day 1 but not Week 13 as assessed by histopathology. Systemic exposure to TA was minimal. TA was observed at high concentrations in the sclera/choroid and retina, to a lesser extent in the iris/ciliary body, and was present only at low concentrations in the aqueous humor, lens, and vitreous.

Conclusions: A single bilateral suprachoroidal injection of 3.2 or 5.2 mg TA using a microneedle was well tolerated in the albino rabbit. Systemic exposure to TA was minimal, and absorption of TA into the posterior segment of the eye was observed with minimal TA exposure to the anterior segment of the eye. These data suggest that suprachoroidal drug delivery is well tolerated, results in distribution of TA to the sclera/choroid and retina, structures that are important targets for anti-inflammatories in posterior segment disease, and limits TA exposure in the anterior segment.

Keywords: 620 ocular irritancy/toxicity testing • 452 choroid • 688 retina  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.